Leveraging detailed information about chemotherapy, radiation, hormone-modulating therapy, and HER2-targeted agents, we found that most childhood cancer survivors were prescribed guideline-concordant breast cancer treatment with similar frequency to controls, albeit with apparent therapeutic tradeoffs considering childhood cancer treatment and comorbidity history. This evidence concerns the gene ERBB2 and breast cancer.